Description
The fibrate class of hypolipidemic drugs such as clofibrate and fenofibrate elicit their effects by binding to and activating peroxisome proliferator-activated receptor α (PPARα). Cetaben is a unique, PPARα-independent peroxisome proliferator with hypolipidemic activity, characterized by reduction in serum triglyceride and cholesterol concentrations in rats.{13454} In male wistar rats, cetaben increased the activity of all peroxisomal enzymes examined in liver and kidney, whereas clofibrate showed a varied regulatory pattern.{13450} In addition to its effects on peroxisomes, cetaben inhibits cholesterol synthesis in the human hepatoma Hep-G2 cells resulting in reversible changes in Golgi morphology.{13452,13453} It also blocked triglyceride synthesis by 99% and reduced cholesterol ester synthesis by >70% at a concentration of 50 µM in these same cells.{13453}
Formal name: 4-(hexadecylamino)-benzoic acid
Synonyms: Hexadecylamino-p-amino Benzoic Acid
Molecular weight: 361.6
CAS: 55986-43-1
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors|Sterol Biosynthesis||Research Area|Cardiovascular System|Lipids & Lipoproteins||Research Area|Endocrinology & Metabolism|Hormones & Receptors|PPARs||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity